{"DataElement":{"publicId":"8003360","version":"1","preferredName":"Patient Mitogen-Activated Protein Kinase Pathway Inhibitor Receive Prior CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator","preferredDefinition":"A questions which asks if patient has received MAPK pathway inhibitor agents prior to study enrollment.","longName":"PT_PRIOR_MAPKP_RECVD_IND","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"8003359","version":"1","preferredName":"Patient Mitogen-Activated Protein Kinase Pathway Inhibitor Receive Prior","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Mitogen-activated protein kinases (MAPKs) are serine-threonine protein kinases activated in response to a variety of extracellular stimuli and encoded by a multigene family. The MAPKs are part of complex protein kinase cascades. One of the several classes of MAPKs includes (among other ERKs) the extracellular signal-regulated kinases ERK1 (p44MAPK) and ERK2 (p42MAPK), activated by the RAF/MEK/ERK signaling pathway. ERK1/2 are widely involved in eukaryotic signal transduction. Upon activation, ERKs translocate to the nucleus and phosphorylate nuclear targets. Phosphorylated ERKs form essential dimers with phosphorylated and unphosphorylated ERK partners. Dimerization is part of the mechanism of MAP kinase family action. Mitogen-activated protein kinases (MAPKs) promote entry in the cell cycle.  (from OMIM 601795, 176948, Swiss-Prot P27361, P28482 and NCI)_A set or series of interactions, often forming a network, which biologists have found useful to group together for organizational, historic, biophysical, or other reasons._A class of substances that binds to and inhibits the function or activity of a target._To take, accept, or get something offered._Earlier in time or order.","longName":"2233604v1.0:8003357v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"8003357","version":"1","preferredName":"Mitogen-Activated Protein Kinase Pathway Inhibitor Receive Prior","preferredDefinition":"Mitogen-activated protein kinases (MAPKs) are serine-threonine protein kinases activated in response to a variety of extracellular stimuli and encoded by a multigene family. The MAPKs are part of complex protein kinase cascades. One of the several classes of MAPKs includes (among other ERKs) the extracellular signal-regulated kinases ERK1 (p44MAPK) and ERK2 (p42MAPK), activated by the RAF/MEK/ERK signaling pathway. ERK1/2 are widely involved in eukaryotic signal transduction. Upon activation, ERKs translocate to the nucleus and phosphorylate nuclear targets. Phosphorylated ERKs form essential dimers with phosphorylated and unphosphorylated ERK partners. Dimerization is part of the mechanism of MAP kinase family action. Mitogen-activated protein kinases (MAPKs) promote entry in the cell cycle.  (from OMIM 601795, 176948, Swiss-Prot P27361, P28482 and NCI):A set or series of interactions, often forming a network, which biologists have found useful to group together for organizational, historic, biophysical, or other reasons.:A class of substances that binds to and inhibits the function or activity of a target.:To take, accept, or get something offered.:Earlier in time or order.","longName":"8003357v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitogen-Activated Protein Kinase","conceptCode":"C16376","definition":"Mitogen-activated protein kinases (MAPKs) are serine-threonine protein kinases activated in response to a variety of extracellular stimuli and encoded by a multigene family. The MAPKs are part of complex protein kinase cascades. One of the several classes of MAPKs includes (among other ERKs) the extracellular signal-regulated kinases ERK1 (p44MAPK) and ERK2 (p42MAPK), activated by the RAF/MEK/ERK signaling pathway. ERK1/2 are widely involved in eukaryotic signal transduction. Upon activation, ERKs translocate to the nucleus and phosphorylate nuclear targets. Phosphorylated ERKs form essential dimers with phosphorylated and unphosphorylated ERK partners. Dimerization is part of the mechanism of MAP kinase family action. Mitogen-activated protein kinases (MAPKs) promote entry in the cell cycle.  (from OMIM 601795, 176948, Swiss-Prot P27361, P28482 and NCI)","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Pathway","conceptCode":"C54214","definition":"A set or series of interactions, often forming a network, which biologists have found useful to group together for organizational, historic, biophysical, or other reasons.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Inhibitor","conceptCode":"C154898","definition":"A class of substances that binds to and inhibits the function or activity of a target.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D57E6FAE-01E6-36DD-E053-4EBD850A3490","latestVersionIndicator":"Yes","beginDate":"2022-01-13","endDate":null,"createdBy":"GALITG","dateCreated":"2022-01-13","modifiedBy":"ONEDATA","dateModified":"2022-01-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D57E6FAE-01F7-36DD-E053-4EBD850A3490","latestVersionIndicator":"Yes","beginDate":"2022-01-13","endDate":null,"createdBy":"GALITG","dateCreated":"2022-01-13","modifiedBy":"ONEDATA","dateModified":"2022-01-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6343337","version":"1","preferredName":"CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator","preferredDefinition":"Terminology codelist used with Yes No Unknown or Not Applicable Response within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"NY","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"2","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6F9FC413-3EDC-2FFB-E053-F662850AA144","beginDate":"2018-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-06-27","modifiedBy":"ONEDATA","dateModified":"2018-06-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"5676138","version":"1","preferredName":"Yes","longName":"5676138","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49204933-EF64-01C8-E053-F662850A7582","latestVersionIndicator":"Yes","beginDate":"2017-02-22","endDate":null,"createdBy":"ANDERSONR","dateCreated":"2017-02-22","modifiedBy":"MMADDINENI","dateModified":"2024-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6F9FC413-3EF1-2FFB-E053-F662850AA144","beginDate":"2018-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-06-27","modifiedBy":"ONEDATA","dateModified":"2018-06-27","deletedIndicator":"No"},{"value":"NA","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"5043360","version":"1","preferredName":"Not Applicable","longName":"5043360","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2421E11B-65A6-151D-E050-BB89AD4378BB","latestVersionIndicator":"Yes","beginDate":"2015-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-11-09","modifiedBy":"DWARZEL","dateModified":"2018-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"73F48F3A-1DF1-2954-E053-F662850A5947","beginDate":"2018-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-21","modifiedBy":"ONEDATA","dateModified":"2018-08-21","deletedIndicator":"No"},{"value":"U","valueDescription":"Unknown","ValueMeaning":{"publicId":"3104212","version":"1","preferredName":"Unknown","longName":"3104212v1.00","preferredDefinition":"Not known, observed, recorded; or reported as unknown by the data contributor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87F3C580-06F4-1DC3-E040-BB89AD434E7E","latestVersionIndicator":"Yes","beginDate":"2010-06-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":"Concept annotated for UPitt/TCGA.  Ylu, 01/30/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"73F48F3A-1DFD-2954-E053-F662850A5947","beginDate":"2018-06-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-21","modifiedBy":"ONEDATA","dateModified":"2018-08-21","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6343336","version":"1","preferredName":"CDISC SDTM Yes No Unknown or Not Applicable Response Terminology Indicator","preferredDefinition":"A term that is used to indicate a question with permissible values of yes/no/unknown/not applicable.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"C66742:C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CDISC SDTM Yes No Unknown or Not Applicable Response Terminology","conceptCode":"C66742","definition":"Terminology codelist used with Yes No Unknown or Not Applicable Response within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F9FC413-3E96-2FFB-E053-F662850AA144","latestVersionIndicator":"Yes","beginDate":"2018-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-06-27","modifiedBy":"ONEDATA","dateModified":"2018-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"6F9FC413-3EA7-2FFB-E053-F662850AA144","latestVersionIndicator":"Yes","beginDate":"2018-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-06-27","modifiedBy":"ZHWENDY","dateModified":"2023-12-12","changeDescription":"Elevated to Standard per governance approval by RA. 2021-6-9 ak  12/18/18 TT released/MC. 8-21-18 edit to PVs/CDISC revised submission values; tt.  Created as part of CDISC mapping task. 6.27.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Has patient received any prio","type":"Preferred Question Text","description":"Has patient received any prior MAPK pathway inhibitor therapy?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Has the patient had prior treatment with a MAP kinase inhibitor combination?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D57AD14F-BD4B-60A4-E053-4EBD850A6B92","latestVersionIndicator":"Yes","beginDate":"2022-01-13","endDate":null,"createdBy":"GALITG","dateCreated":"2022-01-13","modifiedBy":"KUMMEROA","dateModified":"2023-03-28","changeDescription":null,"administrativeNotes":"2023.3.28 AQT added per ticket request CADSR0002221. ak","unresolvedIssues":null,"deletedIndicator":"No"}}